Maria-clemencia E. Hernandez

Basel, BS, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

A Phase 2b Multicenter Study to Evaluate Basmisanil as an Adjunctive Treatment in Patients With Cognitive Impairment Associated With Schizophrenia.

A Phase 2b Multicenter Study to Evaluate Basmisanil as an Adjunctive Treatment in Patients With Cognitive Impairment Associated With Schizophrenia.

Journal: The Journal of clinical psychiatry

Published: April 15, 2026

Excess EEG beta-band oscillations in Dup15q syndrome correlate with clinical severity.

Excess EEG beta-band oscillations in Dup15q syndrome correlate with clinical severity.

Journal: Translational psychiatry

Published: July 03, 2025

Preclinical pharmacology of alogabat: a novel GABAA-α5 positive allosteric modulator targeting neurodevelopmental disorders with impaired GABAA signaling.

Preclinical pharmacology of alogabat: a novel GABAA-α5 positive allosteric modulator targeting neurodevelopmental disorders with impaired GABAA signaling.

Journal: Frontiers in pharmacology

Published: May 09, 2025

SST interneurons facilitate dendritic calcium signaling via tonic activation of α5-GABA receptors.

SST interneurons facilitate dendritic calcium signaling via tonic activation of α5-GABA receptors.

Journal: Neuron

Published: April 16, 2025

RO4938581, a GABAA-α5 negative allosteric modulator rescued behavioral and EEG phenotypes of a mouse model of Dup15q syndrome.

RO4938581, a GABAA-α5 negative allosteric modulator rescued behavioral and EEG phenotypes of a mouse model of Dup15q syndrome.

Journal: Molecular psychiatry

Published: October 30, 2024

γ-Aminobutyric acid transporter and GABAA receptor mechanisms in Slc6a1+/A288V and Slc6a1+/S295L mice associated with developmental and epileptic encephalopathies.

γ-Aminobutyric acid transporter and GABAA receptor mechanisms in Slc6a1+/A288V and Slc6a1+/S295L mice associated with developmental and epileptic encephalopathies.

Journal: Brain communications

Published: July 08, 2023

The molecular basis of drug selectivity for α5 subunit-containing GABAA receptors.

The molecular basis of drug selectivity for α5 subunit-containing GABAA receptors.

Journal: Nature structural & molecular biology

Published: February 28, 2023

SlS5H silencing reveals specific pathogen-triggered salicylic acid metabolism in tomato.

SlS5H silencing reveals specific pathogen-triggered salicylic acid metabolism in tomato.

Journal: BMC plant biology

Published: July 28, 2022

A randomized, double-blind, placebo-controlled phase II trial to explore the effects of a GABAA-α5 NAM (basmisanil) on intellectual disability associated with Down syndrome.

A randomized, double-blind, placebo-controlled phase II trial to explore the effects of a GABAA-α5 NAM (basmisanil) on intellectual disability associated with Down syndrome.

Journal: Journal of neurodevelopmental disorders

Published: August 10, 2021

Basmisanil, a highly selective GABAA-α5 negative allosteric modulator: preclinical pharmacology and demonstration of functional target engagement in man.

Basmisanil, a highly selective GABAA-α5 negative allosteric modulator: preclinical pharmacology and demonstration of functional target engagement in man.

Journal: Scientific reports

Published: October 09, 2020

Sparsification of AP firing in adult-born hippocampal granule cells via voltage-dependent α5-GABAA receptors.

Sparsification of AP firing in adult-born hippocampal granule cells via voltage-dependent α5-GABAA receptors.

Journal: Cell reports

Published: July 09, 2020

Enhanced Dendritic Inhibition and Impaired NMDAR Activation in a Mouse Model of Down Syndrome.

Enhanced Dendritic Inhibition and Impaired NMDAR Activation in a Mouse Model of Down Syndrome.

Journal: The Journal of neuroscience : the official journal of the Society for Neuroscience

Published: October 22, 2018

Showing 1-12 of 22

Last Updated: 09/26/2026